Everolimus

Everolimus Properties

Melting point	NA
Boiling point	998.7±75.0 °C(Predicted)
Density	1.18±0.1 g/cm3(Predicted)
Flash point	2℃
storage temp.	-20°C
solubility	Soluble in DMSO (up to 100 mg/ml) or in Ethanol (up to 100 mg/ml).
form	solid
pka	10.40±0.70(Predicted)
color	White
Water Solubility	Soluble in dimethysulfoxide,ethanol and chloroform. Slightly soluble in water.
Stability	Hygroscopic
InChIKey	HKVAMNSJSFKALM-GKUWKFKPSA-N

SAFETY

Risk and Safety Statements

Symbol(GHS)	GHS08,GHS09
Signal word	Warning
Hazard statements	H351-H361fd-H373-H410
Precautionary statements	P202-P260-P273-P280-P308+P313-P391
Hazard Codes	T,Xn,F
Risk Statements	48/25-36-20/21/22-11
Safety Statements	45-36/37-26-16
RIDADR	UN 1648 3 / PGII
WGK Germany	2
F	10
HS Code	29349990

Everolimus price More Price(6)

Manufacturer	Product number	Product description	CAS number	Packaging	Price	Updated	Buy
Sigma-Aldrich(India)	SML2282	Everolimus ≥95% (HPLC)	159351-69-6	10MG	₹12784.33	2022-06-14	Buy
Sigma-Aldrich(India)	SML2282	Everolimus ≥95% (HPLC)	159351-69-6	50MG	₹51483.7	2022-06-14	Buy
Sigma-Aldrich(India)	E-068	Everolimus solution 1.0?mg/mL in acetonitrile, ampule of 1?mL, certified reference material, Cerilliant?	159351-69-6	1ML	₹33688.9	2022-06-14	Buy
Sigma-Aldrich(India)	94687	Everolimus analytical standard	159351-69-6	10MG	₹17731.35	2022-06-14	Buy
ottokemi	E 1800	Everolimus 90%	159351-69-6	10mg	₹11709	2022-05-26	Buy

Product number	Packaging	Price	Buy
SML2282	10MG	₹12784.33	Buy
SML2282	50MG	₹51483.7	Buy
E-068	1ML	₹33688.9	Buy
94687	10MG	₹17731.35	Buy
E 1800	10mg	₹11709	Buy

Everolimus Chemical Properties,Uses,Production

Description

Everolimus, an oral immunosuppressant for the treatment of kidney and heart transplant rejection, is the 40-O-(2-hydroxyethyl) derivative of rapamycin. It has immunosuppressive properties similar to those of rapamycin, but with improved pharmacokinetic profile. Everolimus, like rapamycin, is a proliferation signal inhibitor that exerts its immunosuppressive effect by inhibiting the activation of p70 S6 kinase, thereby blocking growth factor-driven proliferation of T cells, B cells and vascular smooth muscle cells, and arresting cell cycle at the G1 phase. Inhibition of p70 S6 kinase activation by everolimus and rapamycin is mediated by their binding to FKBP12 (FK506 binding-protein 12). Everolimus inhibits FK506 binding to FKBP12 with an IC50 of 1.8–2.6 nM, and it is about 3- to 5-fold less potent than rapamycin (IC50=0.4–0.9 nM). The in vitro immunosuppressive activity of everolimus is also slightly less than that of rapamycin as demonstrated in a mixed lymphocyte reaction (MLR) assay (IC50=0.2–1.6 nM versus 0.07–0.5 nM, respectively) and in antigen-specific human helper T-cell clones (IC50=0.05–0.17nM versus 0.014–0.37nM, respectively). However, the in vivo immunosuppressive activity of oral everolimus 1–5 mg/ kg/day is similar to that of rapamycin at equivalent doses in rat models of renal or cardiac transplantation, localized graft-versus-host disease, and autoimmune glomerulonephritis. The recommended dosage of everolimus is 0.75 mg twice daily, and it is used in combination with cyclosporine microemulsion and corticosteroids.

Chemical Properties

Off White Solid

Uses

Everolimus (IX) (SDZ-RAD), was developed by Novartis as an immunosuppressant to be used in conjunction with cyclosporin in transplantation allograft rejection and was recently approved in the US in 2003. Another natural product that had been approved for use in transplantation is rapamycin (sirolimus) as an inejectable agent. In an attempt to develop an orally bioavailable immunosuppressant agent, many companies attempted modification of rapamycin itself.

Definition

ChEBI: Everolimus is a macrocyclic lactone that is rapamycin in which the hydroxy group attached to the cyclohexyl moiety has been converted into the corresponding 2-hydroxyethyl ether. It is an immunosuppressant and antineoplastic agent. It has a role as an antineoplastic agent, an immunosuppressive agent, a mTOR inhibitor, an anticoronaviral agent and a geroprotector. It is a primary alcohol, a secondary alcohol, an ether, a cyclic ketone, a cyclic acetal and a macrolide lactam. It is functionally related to a member of sirolimus.

General Description

Everolimus, sold under trade names including Zortress^?, Certican, and Afinitor^?, is an immunosuppressant drug used to prevent rejection of organ transplants and to treat renal cell cancer and other tumors. This Certified Spiking Solution^? is suitable as starting material for calibrators, controls, or linearity standards for therapeutic drug monitoring or clinical and diagnostic testing of everolimus in patient whole blood samples by LC-MS/MS.

Everolimus Preparation Products And Raw materials

Raw materials

Preparation Products

40-O-[2-(t-butyldimethylsilyl)oxy]ethyl rapamycin

Everolimus Suppliers

Global( 553)Suppliers

Supplier	Tel	Country	ProdList	Advantage	Inquiry
Jigs Chemical ltd	+919099003427	Gujarat, India	239	58	Inquiry
Gufic Group	+91-2267261000 +91-2267261000	Maharashtra, India	22	58	Inquiry
Rivashaa Agrotech Biopharma Pvt. Ltd.	+91-26463395 +91-7926462688	Gujarat, India	1615	58	Inquiry
Ralington Pharma	+91-7948911722 +91-9687771722	Gujarat, India	1350	58	Inquiry
Sakar Healthcare	+91-8976292690 +91-9967572302	Gujarat, India	47	58	Inquiry
Sumar Biotech LLP	+91-7984183709 +91-9824575381	Gujarat, India	22	58	Inquiry
BDR Pharmaceuticals International Pvt Ltd	+91-2240560560 +91-7718884418	Maharashtra, India	206	58	Inquiry
Concord Biotech Limited	+91-2714398200 +91-2714398200	Gujarat, India	22	58	Inquiry
Humble Healthcare Limited	+91-9720093000 +91-8006400378	Uttar Pradesh, India	141	58	Inquiry
AKASH PHARMA EXPORTS	+91-9388123451 +91-9846039283	Kerela, India	470	58	Inquiry

Supplier	Advantage
Jigs Chemical ltd	58
Gufic Group	58
Rivashaa Agrotech Biopharma Pvt. Ltd.	58
Ralington Pharma	58
Sakar Healthcare	58
Sumar Biotech LLP	58
BDR Pharmaceuticals International Pvt Ltd	58
Concord Biotech Limited	58
Humble Healthcare Limited	58
AKASH PHARMA EXPORTS	58

Everolimus Spectrum

Everolimus(159351-69-6)¹HNMR

159351-69-6(Everolimus)Related Search:

Rapamycin Argatroban Everolimus Impurity 1 Etofenamate Etoposide

Everolimus O-Ethyl Impurity Exemestane Everolimus Ring-Opening Impurity Everolimus Related Compound 3 2,6-di-tert-butyl-4-methylene-2,5-cyclohexadienone

2-(tert-butyldiMethylsilyl )oxyl alcohol trifluorin Methanesulfonate Ethyleneglycol bistriflate Methanesulfonic acid, trifluoro-, 2-hydroxyethyl ester EveroliMus iMpurity EveroliMus-d4

BIS(T-BUTYLDIMETHYLSILOXY)ETHANE Everolimus 28-Ethylhydroxy Impurity Everolimus Impurity 2

chevron_left

1of4

chevron_right

Rapamycin, 42-O-(2-hydroxyethyl)- Everolimus Certican CERTICAN(R) EveroliMus(RAD-001) (1R,9S,12S,15R,16Z,18R,19R,21R,23S,24Z,26Z,28Z,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-Methoxycyclohexyl]propan-2-yl]-19,30-diMethoxy-15,17,21,23,29,35-hexaMethyl-11,36-dioxa-4-azatricyclo[30.3.1.0^{4,9}]hexatriaconta-16,2 EveroliMus API 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine, rapamycin deriv Everolimus solution Everolimus, >=98% 42-O-(2-Hydroxyethyl)-rapamycin Certica RAD-001 SDZRAD Everolimus（mixture of isomers） Everolimus powder CERTICAN; ZORTRESS; AFINITOR Everolimus 159351-69-6 40-O-(2-Hydroxyethyl) Rapamycin Everolimus (~90% pure) Everolimus USP/EP/BP Everolimus AFINITOR Everolimus (RAD-001, SDZ-RAD) MF No.: 230MF10023 US-DMF ready US-DMF No.: 032020 EverolimusQ: What is Everolimus Q: What is the CAS Number of Everolimus Q: What is the storage condition of Everolimus EI 38 EI38 EI-38 NSC 34858 NSC34858 NSC-34858 Afinitor Zortress EVEROLIMUS(2.0% BHT) EVEROLIMUS(WITHOUT BHT) According to the dimension of therapy (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-((R)-1-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)propan-2-yl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1]oxa[4]azacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentaone Yimosi Everolimus (Everolimus) Apoptosis,inhibit,FK506-binding protein,mTOR,RAD 001,Mammalian target of Rapamycin,RAD-001,FKBP,Inhibitor,Everolimus,Autophagy Ivolimus 159351-69-6 159351-69-7 C53H83NO14 95822 Akt mTOR PI3K Anti-cancer&immunity PI3K/Akt/mTOR Inhibitor Antineoplastic protein kinase inhibitors mTOR inhibitor Certican, Zortress, Afinitor Everolimus All Inhibitors